)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Tenax Therapeutics
Tenax Therapeutics (TENX) investor relations material
Tenax Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary12 May, 2026
Executive summary
Completed randomization of over 230 patients in the Phase 3 LEVEL study, with topline data expected in Q3 2026.
LEVEL-2 global Phase 3 trial enrollment ongoing, completion anticipated by end of 2027.
Strengthened leadership with new CFO, CCO, and EVP of Clinical Development and Strategy appointments.
Financial highlights
Cash and cash equivalents totaled $118.8 million as of March 31, 2026, expected to fund operations through at least Q1 2028.
R&D expenses rose to $11.5 million, up from $5.7 million year-over-year, driven by increased clinical development costs.
G&A expenses decreased to $5.0 million from $5.7 million year-over-year, mainly due to lower stock-based compensation.
Net loss widened to $15.7 million from $10.4 million year-over-year.
Outlook and guidance
Topline data from the LEVEL Phase 3 study expected in Q3 2026.
LEVEL-2 trial enrollment to complete by end of 2027.
Cash runway projected through at least Q1 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tenax Therapeutics
- Director elections and auditor ratification headline the June 2026 annual meeting agenda.TENX
Proxy filing22 Apr 2026 - Annual meeting to elect directors, ratify auditor, and review governance and compensation.TENXProxy filing22 Apr 2026
- Seeks to raise up to $300 million for late-stage cardiopulmonary drug development via shelf registration.TENXRegistration filing24 Mar 2026
- LEVEL trial enrollment finished early; global expansion and Q3 results expected.TENXLeerink Global Healthcare Conference 202610 Mar 2026
- Levosimendan targets a major unmet need in PH-HFPEF, advancing in late-stage trials.TENXCorporate presentation10 Mar 2026
- LEVEL and LEVEL-2 trials advanced, net loss widened, cash reserves support operations through 2027.TENXQ4 202510 Mar 2026
- Levosimendan's Phase III program advances with strong clinical data and broad market potential.TENXGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- Phase 3 trials for oral levosimendan in PH-HFpEF expand, with strong funding and patent protection.TENXLeerink’s Global Healthcare Conference 202526 Dec 2025
- Phase III oral therapy for PH-HFpEF shows promise, with strong clinical and market potential.TENX24th Annual Needham Virtual Healthcare Conference23 Dec 2025
Next Tenax Therapeutics earnings date
Q2 202612 Aug, 2026
Tenax Therapeutics
Next Tenax Therapeutics earnings date
Q2 202612 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage